Other Events ·
SELLAS Life Sciences Group, Inc. announced that a sole arbitrator dismissed the company's claims in a binding…
SLSSELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. announced that a sole arbitrator dismissed the company's claims in a binding arbitration against 3D Medicines, Inc. administered by the Hong Kong International Arbitration Centre. The company is required to pay approximately $1.0 million in administratively allocated legal fees and costs to 3D Medicines. Despite the dispute, 3D Medicines will continue developing and commercializing galinpepimut-S in Greater China, with $191.5 million in potential future milestone payments remaining as of March 31, 2026. Additionally, the company reported an estimated unaudited cash and cash equivalents position of $138.3 million as of June 30, 2026. SELLAS Life Sciences Group, Inc. is a biopharmaceutical company focused on developing therapies for cancer.